JP2020501563A - 細菌メタゲノム解析による胃癌診断方法 - Google Patents
細菌メタゲノム解析による胃癌診断方法 Download PDFInfo
- Publication number
- JP2020501563A JP2020501563A JP2019531914A JP2019531914A JP2020501563A JP 2020501563 A JP2020501563 A JP 2020501563A JP 2019531914 A JP2019531914 A JP 2019531914A JP 2019531914 A JP2019531914 A JP 2019531914A JP 2020501563 A JP2020501563 A JP 2020501563A
- Authority
- JP
- Japan
- Prior art keywords
- sample
- gastric cancer
- subject
- bacterial
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 113
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 113
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 113
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 101
- 238000004458 analytical method Methods 0.000 title abstract description 52
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 241000894006 Bacteria Species 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 44
- 210000004369 blood Anatomy 0.000 claims description 46
- 239000008280 blood Substances 0.000 claims description 46
- 210000002700 urine Anatomy 0.000 claims description 43
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 241001608234 Faecalibacterium Species 0.000 claims description 11
- 241000588923 Citrobacter Species 0.000 claims description 10
- 241001528480 Cupriavidus Species 0.000 claims description 9
- 241000192700 Cyanobacteria Species 0.000 claims description 9
- 241001112692 Peptostreptococcaceae Species 0.000 claims description 9
- 238000012300 Sequence Analysis Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 241000589291 Acinetobacter Species 0.000 claims description 6
- 241001655314 Brevibacteriaceae Species 0.000 claims description 6
- 241000588653 Neisseria Species 0.000 claims description 6
- 241000605861 Prevotella Species 0.000 claims description 6
- 241000466670 Adlercreutzia Species 0.000 claims description 5
- 241000193818 Atopobium Species 0.000 claims description 5
- 241001655328 Bifidobacteriales Species 0.000 claims description 5
- 241000947912 Cardiobacteriales Species 0.000 claims description 5
- 241001600129 Delftia Species 0.000 claims description 5
- 241000305071 Enterobacterales Species 0.000 claims description 5
- 241000192041 Micrococcus Species 0.000 claims description 5
- 241001430197 Mollicutes Species 0.000 claims description 5
- 241000160321 Parabacteroides Species 0.000 claims description 5
- 241001466451 Stramenopiles Species 0.000 claims description 5
- 241000131694 Tenericutes Species 0.000 claims description 5
- 241001148134 Veillonella Species 0.000 claims description 5
- 210000003763 chloroplast Anatomy 0.000 claims description 5
- 241000702460 Akkermansia Species 0.000 claims description 4
- 241001430332 Bifidobacteriaceae Species 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241001464948 Coprococcus Species 0.000 claims description 4
- 241000588921 Enterobacteriaceae Species 0.000 claims description 4
- 241001609976 Leuconostocaceae Species 0.000 claims description 4
- 241000589323 Methylobacterium Species 0.000 claims description 4
- 241000588656 Neisseriaceae Species 0.000 claims description 4
- 241000266824 Oscillospira Species 0.000 claims description 4
- 241000192001 Pediococcus Species 0.000 claims description 4
- 241000692843 Porphyromonadaceae Species 0.000 claims description 4
- 241000692844 Prevotellaceae Species 0.000 claims description 4
- 241000192031 Ruminococcus Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 241001493533 Streptophyta Species 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 241000589218 Acetobacteraceae Species 0.000 claims description 3
- 241001430266 Methylocystaceae Species 0.000 claims description 3
- 241000692845 Rikenellaceae Species 0.000 claims description 3
- 241000131972 Sphingomonadaceae Species 0.000 claims description 3
- 241001183271 Verrucomicrobiaceae Species 0.000 claims description 3
- 241000589519 Comamonas Species 0.000 claims 2
- 241001277521 Oxalobacteraceae Species 0.000 claims 2
- 210000005087 mononuclear cell Anatomy 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 20
- 238000011161 development Methods 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 238000013399 early diagnosis Methods 0.000 abstract description 5
- 230000000235 effect on cancer Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 241000894007 species Species 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 244000005700 microbiome Species 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 241001468125 Exiguobacterium Species 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000203069 Archaea Species 0.000 description 3
- 241000588771 Morganella <proteobacterium> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001212279 Neisseriales Species 0.000 description 3
- 241000589180 Rhizobium Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000253389 Methylobacteriaceae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241001600130 Comamonadaceae Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000785902 Odoribacter Species 0.000 description 1
- 241001112744 Planococcaceae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- 241001183192 Verrucomicrobiae Species 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Botany (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
(a)被検者サンプルから分離した細胞外小胞からDNAを抽出する段階;
(b)前記抽出したDNAに対して配列番号1及び配列番号2のプライマー対を用いてPCRを行う段階;及び
(c)前記PCR産物の配列解析により正常人由来サンプルと細菌由来細胞外小胞の含量増減を比較する段階。
(a)被検者サンプルから分離した細胞外小胞からDNAを抽出する段階;
(b)前記抽出したDNAに対して配列番号1及び配列番号2のプライマー対を利用してPCRを行う段階;及び
(c)前記PCR産物の配列解析により正常人由来サンプルと細菌由来細胞外小胞の含量増減を比較する段階。
(a)被検者サンプルから分離した細胞外小胞からDNAを抽出する段階;
(b)前記抽出したDNAに対して配列番号1及び配列番号2のプライマー対を用いてPCRを行う段階;及び
(c)前記PCR産物の配列解析により正常人由来サンプルと細菌由来細胞外小胞の含量増減を比較する段階。
(b)前記抽出したDNAに対して配列番号1及び配列番号2のプライマー対を用いてPCRを行う段階;及び
(c)前記PCR産物の配列解析により正常人由来サンプルと細菌由来細胞外小胞の含量増減を比較する段階を含む胃癌診断のための情報提供方法を提供する。
実施例2.血液、大便、及び尿から小胞分離及びDNA抽出
実施例3.血液、大便、及び尿から抽出したDNAを利用したメタゲノム解析
実施例4.血液から分離した細菌由来小胞メタゲノム解析基盤の胃癌診断模型
実施例5.尿から分離した細菌由来小胞メタゲノム解析基盤の胃癌診断模型
実施例6.大便から分離した細菌由来小胞メタゲノム解析基盤の胃癌診断模型
Claims (16)
- 下記の段階を含むことを特徴とする、胃癌診断のための情報提供方法:
(a)被検者サンプルから分離した細胞外小胞からDNAを抽出する段階;
(b)前記抽出したDNAに対して配列番号1及び配列番号2のプライマー対を用いてPCRを行う段階;及び
(c)前記PCR産物の配列解析により正常人由来サンプルと細菌由来細胞外小胞の含量増減を比較する段階。 - 前記(c)段階で被検者尿サンプルから分離したVerrucomicrobia、及びCyanobacteria、被検者大便サンプルから分離したTenericutes、及びCyanobacteriaからなる群から選択される1種以上の門(phylum)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項1に記載の情報提供方法。
- 前記(c)段階で被検者尿サンプルから分離したVerrucomicrobiae、及びChloroplast、被検者大便サンプルから分離したMollicutesからなる群から選択される1種以上の綱(class)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項1に記載の情報提供方法。
- 前記(c)段階で被検者血液サンプルから分離したCardiobacteriales、被検者尿サンプルから分離したRF39、Stramenopiles、Verrucomicrobiales、Sphingomonadales、Bifidobacteriales、Streptophyta、及びAeromonadales、被検者大便サンプルから分離したRF39、Neisseriales、及びEnterobacterialesからなる群から選択される1種以上の目(order)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項1に記載の情報提供方法。
- 前記(c)段階で被検者血液サンプルから分離したMethylocystaceae、Exiguobacteraceae、Peptostreptococcaceae、Brevibacteriaceae、Mogibacteriaceae、Acetobacteraceae、Rikenellaceae、及びLeuconostocaceae、被検者尿サンプルから分離したExiguobacteraceae、Porphyromonadaceae、Prevotellaceae、Verrucomicrobiaceae、Sphingomonadaceae、Bifidobacteriaceae、Methylobacteriaceae、Planococcaceae、及びComamonadaceae、被検者大便サンプルから分離したPeptostreptococcaceae、Neisseriaceae、Enterobacteriaceae、Staphylococcaceae、Oxalobacteraceae、Moraxellaceae、及びPlanococcaceaeからなる群から選択される1種以上の科(family)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項1に記載の情報提供方法。
- 前記(c)段階で被検者血液サンプルから分離したCupriavidus、Proteus、Atopobium、Micrococcus、Odoribacter、Faecalibacterium、Veillonella、Citrobacter、Delftia、Weissella、及びLeuconostoc、被検者尿サンプルから分離したMorganella、Rhizobium、Exiguobacterium、Proteus、Parabacteroides、Adlercreutzia、Prevotella、Acinetobacter、Akkermansia、Oscillospira、Bifidobacterium、Faecalibacterium、Ruminococcus、Coprococcus、Pediococcus、及びCitrobacter、被検者大便サンプルから分離したCupriavidus、Proteus、Methylobacterium、Faecalibacterium、Neisseria、Staphylococcus、及びAcinetobacterからなる群から選択される1種以上の属(genus)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項1に記載の情報提供方法。
- 前記被検者サンプルは、血液、尿、または大便であることを特徴とする、請求項1に記載の情報提供方法。
- 前記血液は、全血、血清、血漿、または血液単核球であることを特徴とする、請求項7に記載の情報提供方法。
- 下記の段階を含むことを特徴とする、胃癌診断方法:
(a)被検者サンプルから分離した細胞外小胞からDNAを抽出する段階;
(b)前記抽出したDNAに対して配列番号1及び配列番号2のプライマー対を用いてPCRを行う段階;及び
(c)前記PCR産物の配列解析により正常人由来サンプルと細菌由来細胞外小胞の含量増減を比較する段階。 - 前記(c)段階で被検者尿サンプルから分離したVerrucomicrobia、及びCyanobacteria、被検者大便サンプルから分離したTenericutes、及びCyanobacteriaからなる群から選択される1種以上の門(phylum)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項9に記載の胃癌診断方法。
- 前記(c)段階で被検者尿サンプルから分離したVerrucomicrobiae、及びChloroplast、被検者大便サンプルから分離したMollicutesからなる群から選択される1種以上の綱(class)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項9に記載の胃癌診断方法。
- 前記(c)段階で被検者血液サンプルから分離したCardiobacteriales、被検者尿サンプルから分離したRF39、Stramenopiles、Verrucomicrobiales、Sphingomonadales、Bifidobacteriales、Streptophyta、及びAeromonadales、被検者大便サンプルから分離したRF39、Neisseriales、及びEnterobacterialesからなる群から選択される1種以上の目(order)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項9に記載の胃癌診断方法。
- 前記(c)段階で被検者血液サンプルから分離したMethylocystaceae、Exiguobacteraceae、Peptostreptococcaceae、Brevibacteriaceae、Mogibacteriaceae、Acetobacteraceae、Rikenellaceae、及びLeuconostocaceae、被検者尿サンプルから分離したExiguobacteraceae、Porphyromonadaceae、Prevotellaceae、Verrucomicrobiaceae、Sphingomonadaceae、Bifidobacteriaceae、Methylobacteriaceae、Planococcaceae、及びComamonadaceae、被検者大便サンプルから分離したPeptostreptococcaceae、Neisseriaceae、Enterobacteriaceae、Staphylococcaceae、Oxalobacteraceae、Moraxellaceae、及びPlanococcaceaeからなる群から選択される1種以上の科(family)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項9に記載の胃癌診断方法。
- 前記(c)段階で被検者血液サンプルから分離したCupriavidus、Proteus、Atopobium、Micrococcus、Odoribacter、Faecalibacterium、Veillonella、Citrobacter、Delftia、Weissella、及びLeuconostoc、被検者尿サンプルから分離したMorganella、Rhizobium、Exiguobacterium、Proteus、Parabacteroides、Adlercreutzia、Prevotella、Acinetobacter、Akkermansia、Oscillospira、Bifidobacterium、Faecalibacterium、Ruminococcus、Coprococcus、Pediococcus、及びCitrobacter、被検者大便サンプルから分離したCupriavidus、Proteus、Methylobacterium、Faecalibacterium、Neisseria、Staphylococcus、及びAcinetobacterからなる群から選択される1種以上の属(genus)細菌由来細胞外小胞の含量増減を比較することを特徴とする、請求項9に記載の胃癌診断方法。
- 前記被検者サンプルは、血液、尿、または大便であることを特徴とする、請求項9に記載の胃癌診断方法。
- 前記血液は、全血、血清、血漿、または血液単核球であることを特徴とする、請求項15に記載の胃癌診断方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160172584 | 2016-12-16 | ||
KR10-2016-0172584 | 2016-12-16 | ||
KR10-2017-0072432 | 2017-06-09 | ||
KR1020170072432A KR101833502B1 (ko) | 2016-12-16 | 2017-06-09 | 세균 메타게놈 분석을 통한 위암 진단방법 |
PCT/KR2017/014860 WO2018111040A1 (ko) | 2016-12-16 | 2017-12-15 | 세균 메타게놈 분석을 통한 위암 진단방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020501563A true JP2020501563A (ja) | 2020-01-23 |
JP6846833B2 JP6846833B2 (ja) | 2021-03-24 |
Family
ID=61726998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019531914A Active JP6846833B2 (ja) | 2016-12-16 | 2017-12-15 | 細菌メタゲノム解析による胃癌診断方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200157632A1 (ja) |
JP (1) | JP6846833B2 (ja) |
KR (1) | KR101833502B1 (ja) |
CN (2) | CN108220410A (ja) |
WO (1) | WO2018111040A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020513799A (ja) * | 2018-02-21 | 2020-05-21 | エムディー ヘルスケア インコーポレイテッドMd Healthcare Inc. | クプリアウィドゥス属細菌由来のナノ小胞及びその使用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102095355B1 (ko) * | 2018-01-12 | 2020-03-31 | 주식회사 엠디헬스케어 | 모르가넬라 속 세균 유래 나노소포 및 이의 용도 |
WO2019139279A1 (ko) * | 2018-01-12 | 2019-07-18 | 주식회사 엠디헬스케어 | 모르가넬라 속 세균 유래 나노소포 및 이의 용도 |
KR102122885B1 (ko) * | 2018-02-23 | 2020-06-15 | 주식회사 엠디헬스케어 | 엑시구오박테리움 속 세균 유래 나노소포 및 이의 용도 |
KR102118199B1 (ko) * | 2018-02-26 | 2020-06-02 | 주식회사 엠디헬스케어 | 아토포비움 속 세균 유래 나노소포 및 이의 용도 |
KR102118198B1 (ko) * | 2018-02-28 | 2020-06-02 | 주식회사 엠디헬스케어 | 리조비움 속 세균 유래 나노소포 및 이의 용도 |
KR102118197B1 (ko) * | 2018-02-28 | 2020-06-02 | 주식회사 엠디헬스케어 | 마이크로코커스 속 세균 유래 나노소포 및 이의 용도 |
KR102118989B1 (ko) * | 2018-03-05 | 2020-06-05 | 주식회사 엠디헬스케어 | 엔히드로박터 세균 유래 나노소포 및 이의 용도 |
KR102101692B1 (ko) * | 2018-03-05 | 2020-04-20 | 주식회사 엠디헬스케어 | 락토바실러스 속 세균 유래 나노소포 및 이의 용도 |
KR102185983B1 (ko) * | 2018-03-06 | 2020-12-03 | 주식회사 엠디헬스케어 | 콜린셀라 속 세균 유래 나노소포 및 이의 용도 |
KR102118993B1 (ko) * | 2018-03-06 | 2020-06-05 | 주식회사 엠디헬스케어 | 프레보텔라 속 세균 유래 나노소포 및 이의 용도 |
KR102118996B1 (ko) * | 2018-03-06 | 2020-06-05 | 주식회사 엠디헬스케어 | 베일로넬라 속 세균 유래 나노소포 및 이의 용도 |
CN109234187B (zh) * | 2018-08-15 | 2021-06-15 | 李晓明 | 一株莠去津降解菌及其应用 |
KR102286042B1 (ko) * | 2019-01-09 | 2021-08-03 | 주식회사 엠디헬스케어 | 데이노코커스 속 세균 유래 나노소포 및 이의 용도 |
JP7291424B2 (ja) * | 2019-01-09 | 2023-06-15 | エムディー ヘルスケア インコーポレイテッド | デイノコッカス属細菌由来ナノ小胞及びその用途 |
KR102285335B1 (ko) * | 2019-02-14 | 2021-08-04 | 주식회사 엠디헬스케어 | 로치아 속 세균 유래 나노소포 및 이의 용도 |
KR102379022B1 (ko) * | 2019-05-24 | 2022-03-28 | 주식회사 엠디헬스케어 | qPCR 분석을 통한 위암 진단방법 |
CA3180044A1 (en) * | 2020-06-11 | 2021-12-16 | Evelo Biosciences, Inc. | Compositions and methods for treating diseases and disorders using oscillospiraceae microbial extracellular vesicles |
KR102542476B1 (ko) | 2020-06-22 | 2023-06-12 | 한국생명공학연구원 | 오도리박터 스플란크니쿠스 또는 이의 배양액을 유효성분으로 포함하는 암 예방 또는 치료용 조성물 |
CN115011710B (zh) * | 2022-02-09 | 2023-09-15 | 江苏省肿瘤医院 | 一种与胃癌预后相关的胃内菌群标志物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013503858A (ja) * | 2009-09-04 | 2013-02-04 | イオン メディックス インコーポレイテッド | グラム陽性細菌由来細胞外ベシクル及びその用途 |
WO2016099076A1 (ko) * | 2014-12-16 | 2016-06-23 | 이화여자대학교 산학협력단 | 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120132183A (ko) * | 2011-05-27 | 2012-12-05 | 포항공과대학교 산학협력단 | 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 |
US9939442B2 (en) | 2011-09-08 | 2018-04-10 | The Regents Of The University Of California | Salivary biomarkers for gastric cancer detection |
KR101445243B1 (ko) | 2014-03-28 | 2014-09-29 | 서울대학교산학협력단 | 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단 |
-
2017
- 2017-06-09 KR KR1020170072432A patent/KR101833502B1/ko active IP Right Grant
- 2017-08-31 CN CN201710769238.4A patent/CN108220410A/zh active Pending
- 2017-08-31 CN CN202210343775.3A patent/CN114717316A/zh active Pending
- 2017-12-15 JP JP2019531914A patent/JP6846833B2/ja active Active
- 2017-12-15 US US16/469,212 patent/US20200157632A1/en not_active Abandoned
- 2017-12-15 WO PCT/KR2017/014860 patent/WO2018111040A1/ko active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013503858A (ja) * | 2009-09-04 | 2013-02-04 | イオン メディックス インコーポレイテッド | グラム陽性細菌由来細胞外ベシクル及びその用途 |
WO2016099076A1 (ko) * | 2014-12-16 | 2016-06-23 | 이화여자대학교 산학협력단 | 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법 |
Non-Patent Citations (4)
Title |
---|
AVILES-JIMENEZ F. ET AL., SCIENTIFIC REPORTS, vol. 4: 4202 (2014), JPN6020024771, ISSN: 0004377806 * |
DICKSVED J. ET AL., JOURNAL OF MEDICAL MICROBIOLOGY, vol. 58 (2009), JPN6020024770, pages 509 - 516, ISSN: 0004377805 * |
TSENG C. ET AL., SCIENTIFIC REPORTS, vol. 6: 20701 (2016 Feb), JPN6020024772, ISSN: 0004377807 * |
YASIR M. ET AL., NUTRITION & DIABETES, vol. 5 (2015), JPN6020024769, pages 153, ISSN: 0004377804 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020513799A (ja) * | 2018-02-21 | 2020-05-21 | エムディー ヘルスケア インコーポレイテッドMd Healthcare Inc. | クプリアウィドゥス属細菌由来のナノ小胞及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
CN108220410A (zh) | 2018-06-29 |
WO2018111040A1 (ko) | 2018-06-21 |
CN114717316A (zh) | 2022-07-08 |
KR101833502B1 (ko) | 2018-03-05 |
US20200157632A1 (en) | 2020-05-21 |
JP6846833B2 (ja) | 2021-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6846833B2 (ja) | 細菌メタゲノム解析による胃癌診断方法 | |
EP3564390B1 (en) | Method for diagnosing colon tumor via bacterial metagenomic analysis | |
JP2020503028A (ja) | 細菌メタゲノム解析による肺癌診断方法 | |
JP7116426B2 (ja) | 細菌メタゲノム分析を通したアルツハイマー型認知症の診断方法 | |
JP7089807B2 (ja) | 細菌メタゲノム分析を通した脳卒中の診断方法 | |
US20220267850A1 (en) | Inflammatory bowel disease diagnostic method by means of bacterial metagenomic analysis | |
JP7152053B2 (ja) | 細菌メタゲノム分析を通したうつ病の診断方法 | |
JP7084637B2 (ja) | 細菌メタゲノム分析を通した前立腺疾患の診断方法 | |
EP3636780B1 (en) | Method for diagnosing autism by analyzing bacterial metagenome | |
US20200199655A1 (en) | Method for diagnosing ovarian cancer through microbial metagenome analysis | |
KR101936006B1 (ko) | 미생물 메타게놈 분석을 통한 방광암 진단방법 | |
KR102063196B1 (ko) | 세균 메타게놈 분석을 통한 과민성장증후군 진단방법 | |
KR102007786B1 (ko) | 세균 메타게놈 분석을 통한 두경부암 진단방법 | |
CN111630189B (zh) | 通过细菌性宏基因组分析来诊断胆管癌的方法 | |
KR101995231B1 (ko) | 세균 메타게놈 분석을 통한 췌장암 진단방법 | |
JP7112125B2 (ja) | 細菌メタゲノム分析を通したリンパ腫の診断方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190805 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201007 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210128 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6846833 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |